Strontium-89 therapy: measurement of absorbed dose to skeletal metastases.

摘要: We report measurements of absorbed dose to vertebral metastases in ten patients referred for /sup 89/Sr therapy disseminated prostatic carcinoma. Patients received a tracer 85/Sr at the time treatment and metastatic strontium retention was monitored scintigraphically 6 mo. Metastatic activity corrected tissue attenuation measured using conjugate view principle, with special care taken eliminate errors due selection region interest. volume determined from high resolution CT images, density inferred Hounsfield number QCT bone mineral calibration Genant Cann. The mean 850 rad/mCi (23 cGy/MBq) range 220-2260 (6 61 cGy/MBq). wide found consistent variation expected arise differences renal plasma clearance (range 0.1-11.81/day) extent skeletal disease (varying two small superscan on (/sup 99m/Tc)MDP images) among studied.